Nimbus secures $200m from Gilead for inhibitor program acquisition
Nimbus Therapeutics secured a $200m from Gilead Sciences in a payment related to the latter’s allosteric Acetyl-CoA Carboxylase (ACC) inhibitor program with NDI-010976 (now GS-0976) which was previously acquired from Nimbus.
